Biomnis
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biomnis - overview
Established
1897
Location
Lyon, -, France
Primary Industry
Healthcare
About
Biomnis provides advanced medical biology services, specializing in diagnostic testing for healthcare providers, laboratories, and patients. The company focuses on genetic testing, oncology, immunology, and prenatal diagnostics, delivering critical insights for patient care. Biomnis, founded in 1897, is headquartered in Lyon, France, and specializes in medical diagnostics. The company underwent restructuring in September 2013 by Bio Alfras SAS, with Duke Street retaining a minority stake.
In June 2015, Eurofins Scientific acquired Biomnis for EUR 220 mn. The company has completed a total of 4 deals with the most recent deal date on June 23, 2015. Eurofins Biomnis specializes in advanced medical biology, offering a wide array of diagnostic services tailored to meet the needs of healthcare providers, laboratories, and patients. Their core product offerings include specialized biological analyses related to genetic testing, oncology, immunology, and prenatal diagnostics.
Key services such as non-invasive prenatal testing (NIPT) for conditions like trisomy 21 utilize simple maternal blood samples, providing crucial information for expectant parents. The company operates across 43 countries and three continents, serving a diverse client base that includes healthcare professionals, hospitals, and diagnostic laboratories seeking reliable and innovative solutions for patient care. Eurofins Biomnis continuously invests in research and development to enhance its product portfolio and maintain its position in medical biology. In 2023, Eurofins Biomnis reported a revenue of EUR 187,583,269.
4 and an EBITDA of EUR 12,216,299. The company generates revenue through a structured transaction model that focuses on B2B partnerships with healthcare institutions and laboratories, engaging in recurring transactions for diagnostic testing services. Biomnis plans to maintain its growth trajectory by investing in the development of new diagnostic products, with specific launches anticipated in the near future, although exact dates are not disclosed. The company aims to expand its operations into new geographic markets, targeting regions in Europe and Asia by 2025.
The acquisition by Eurofins Scientific for EUR 220 mn will support these initiatives, enabling further investment in research and product innovation.
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
www.biomnis.com
Total Amount Raised
Subscriber access only
Biomnis - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Active Biomarkers | - | ||||||||
| Trade Sale | Completed | Biomnis | - | ||||||||
| Restructuring | Completed | Biomnis | - | ||||||||
| Private Debt | Completed | Biomnis | - | ||||||||
| Buyout | Completed | Biomnis | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.